|1.||Meijer, Laurent: 11 articles (01/2015 - 07/2002)|
|2.||Park, David S: 6 articles (08/2006 - 02/2002)|
|3.||Senderowicz, Adrian M: 6 articles (11/2003 - 01/2002)|
|4.||Krystof, Vladimír: 5 articles (01/2012 - 08/2009)|
|5.||Wesierska-Gadek, Józefa: 5 articles (01/2011 - 12/2008)|
|6.||Slack, Ruth S: 5 articles (08/2006 - 02/2002)|
|7.||Galons, Hervé: 4 articles (01/2015 - 09/2005)|
|8.||Jorda, Radek: 4 articles (10/2014 - 07/2010)|
|9.||Strnad, Miroslav: 4 articles (10/2014 - 09/2005)|
|10.||Hassan, Moustapha: 4 articles (07/2014 - 03/2005)|
06/01/2012 - "Diaminothiazoles are a class of compounds that have been reported to show promise in the treatment of cancer by inhibiting cancer cell proliferation and inducing apoptosis, because of their effects on microtubules and as inhibitors of cyclin-dependent kinases. "
01/01/2012 - "We show real-life examples of how these methods have been applied in the case of cyclin-dependent kinases, a family of flexible targets that shows promise in cancer therapy."
01/01/2014 - "Although most functional studies of the role of PFKFB3 in cancer progression have invoked its well-recognized function in the regulation of glycolysis, recent observations have established that PFKFB3 also traffics to the nucleus and that its product, F2,6BP, activates cyclin-dependent kinases (Cdks). "
03/01/2005 - "Cellular cyclin-dependent kinases (CDKs) are required for replication of many viruses and specific pharmacological CDK inhibitors (PCIs) are proving to have surprisingly few negative side effects in clinical trials (against cancer). "
01/01/2003 - "Previous studies have shown that low levels of p27(KIP1), an inhibitor of G1 cyclin-dependent kinases (CDK), are associated with high aggressiveness and poor prognosis in a variety of cancers. "
|2.||Neurodegenerative Diseases (Neurodegenerative Disease)
10/01/2006 - "Chemical inhibitors of cyclin-dependent kinases have great therapeutic potential against various proliferative and neurodegenerative disorders. "
09/19/2002 - "Chemical inhibitors of cyclin-dependent kinases (CDKs) have a great therapeutic potential against various proliferative and neurodegenerative disorders. "
06/01/2000 - "Chemical inhibitors of cyclin-dependent kinases (CDKs) have great therapeutic potential against various proliferative and neurodegenerative disorders. "
12/01/2008 - "Cyclin dependent kinases (cdks) play an important role in the pathogenesis of multiple neurodegenerative diseases. "
08/01/2003 - "There is increasing evidence suggesting that cyclin-dependent kinases (Cdks) that normally regulate cell cycle progression may also be involved in the pathogenesis of neurodegenerative disorders and in the apoptotic death of neurons subjected to various insults. "
|3.||Retinoblastoma (Glioblastoma, Retinal)
08/15/2015 - "Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 that acts by reducing phosphorylation of the tumor suppressor gene retinoblastoma. "
01/19/2011 - "As a critical target for cyclin-dependent kinases (Cdks), the retinoblastoma tumour suppressor protein (pRb) controls early cell cycle progression. "
06/22/2010 - "Using an available small molecule targeting cyclin-dependent kinases (CDKs) 4 and 6, we sought to determine if the specific pattern of retinoblastoma pathway inactivation dictated the response to CDK4/6 inhibitor therapy. "
12/01/2009 - "For example, it is becoming increasingly evident that the master cell cycle regulators, the cyclin-dependent kinases and retinoblastoma-related families, play key roles in the events leading to endosperm formation and development. "
09/01/2006 - "The G1/S and G2/M transitions are critical checkpoints controlled, in part, by cyclin-dependent kinases in the retinoblastoma (RBR)/E2F/DP pathway. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
12/01/2006 - "A strong anti-proliferative efficacy with a relatively low direct cytotoxicity, obtainable with oloumicine and roscovitine (selective cyclin-dependent kinases inhibitors) can represent a new expedient for the therapeutic treatment of MMR deficient colorectal cancers. "
09/01/2009 - "Cyclin-dependent kinases (Cdk) are deregulated in colorectal cancer by silencing of the Cdk inhibitor p16(Ink4a) and other mechanisms. "
07/01/2009 - "Cyclin D1 and cyclin-dependent kinases (CDK) are commonly activated in colorectal cancer. "
11/01/2008 - "Cyclin D1 and cyclin-dependent kinases are commonly activated in colorectal cancer. "
10/01/2002 - "Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells."
|5.||Hepatocellular Carcinoma (Hepatoma)
10/01/2013 - "Given the fact that the aberrant activation of cyclin-dependent kinases (CDK) is frequently observed in hepatocellular carcinomas, we focused on the efficacy of the novel compounds BA-12 and BP-14 that antagonize CDK1/2/5/7 and CDK9. "
10/01/2013 - "Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance."
06/03/2011 - "Hepatocellular carcinoma (HCC) is frequently associated with abnormalities in cell cycle regulation, leading to increased activity of cyclin-dependent kinases (Cdks) due to the loss, or low expression of, Cdk inhibitors. "
06/01/2002 - "Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma."
08/01/2001 - "To investigate the possible roles of p27(KIP1) and p21(WAF1/CIP1), inhibitors of cyclin-dependent kinases, in hepatocellular carcinoma (HCC), we examined p27(KIP1) and p21(WAF1/CIP1) expression in primary HCC with immunohistochemistry and Northern blot hybridization and correlated the results with clinicopathologic features and survival. "
|3.||DNA-Directed RNA Polymerases (RNA Polymerase)
|4.||Tumor Suppressor Proteins (Proteins, Tumor Suppressor)
|7.||Proteins (Proteins, Gene)
|10.||Cyclin-Dependent Kinase Inhibitor p16
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)